[go: up one dir, main page]

BRPI0409789A - vacina de tuberculose com eficácia aperfeiçoada - Google Patents

vacina de tuberculose com eficácia aperfeiçoada

Info

Publication number
BRPI0409789A
BRPI0409789A BRPI0409789-0A BRPI0409789A BRPI0409789A BR PI0409789 A BRPI0409789 A BR PI0409789A BR PI0409789 A BRPI0409789 A BR PI0409789A BR PI0409789 A BRPI0409789 A BR PI0409789A
Authority
BR
Brazil
Prior art keywords
nucleic acid
acid molecules
tuberculosis vaccine
relates
present
Prior art date
Application number
BRPI0409789-0A
Other languages
English (en)
Inventor
Leander Grode
Stefan H E Kaufmann
Borbel Raupach
Juergen Hess
Original Assignee
Max Planck Gesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max Planck Gesellschaft filed Critical Max Planck Gesellschaft
Publication of BRPI0409789A publication Critical patent/BRPI0409789A/pt
Publication of BRPI0409789B1 publication Critical patent/BRPI0409789B1/pt
Publication of BRPI0409789B8 publication Critical patent/BRPI0409789B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

"VACINA DE TUBERCULOSE COM EFICáCIA APERFEIçOADA". A presente invenção refere-se a novas vacinas recombinantes provendo imunidade protetora contra tuberculose. Ainda, a presente invenção refere-se a novas moléculas de ácido nucléico recombinante, vetores contendo as ditas moléculas de ácido nucléico, células transformadas com as ditas moléculas de ácido nucléico e polipeptídeos codificados pelas ditas moléculas de ácido nucléico.
BRPI0409789A 2003-04-23 2004-04-23 célula bacteriana, seus processos de preparação e seu uso, composição, e processo para a preparação de uma vacina viva BRPI0409789B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46464403P 2003-04-23 2003-04-23
PCT/EP2004/004345 WO2004094469A1 (en) 2003-04-23 2004-04-23 Tuberculosis vaccine with improved efficacy

Publications (3)

Publication Number Publication Date
BRPI0409789A true BRPI0409789A (pt) 2006-05-30
BRPI0409789B1 BRPI0409789B1 (pt) 2018-10-16
BRPI0409789B8 BRPI0409789B8 (pt) 2021-05-25

Family

ID=33310924

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0409789A BRPI0409789B8 (pt) 2003-04-23 2004-04-23 célula bacteriana, seus processos de preparação e seu uso, composição, e processo para a preparação de uma vacina viva

Country Status (23)

Country Link
US (2) US7988980B2 (pt)
EP (1) EP1618128B1 (pt)
JP (1) JP4662925B2 (pt)
KR (1) KR101101263B1 (pt)
CN (1) CN1798762B (pt)
AT (1) ATE473238T1 (pt)
AU (1) AU2004232485B2 (pt)
BR (1) BRPI0409789B8 (pt)
CA (1) CA2523084C (pt)
CU (1) CU23608A3 (pt)
CY (1) CY1110793T1 (pt)
DE (1) DE602004028000D1 (pt)
DK (1) DK1618128T3 (pt)
ES (1) ES2344698T3 (pt)
HR (1) HRP20100395T1 (pt)
MX (1) MXPA05011360A (pt)
PL (1) PL1618128T3 (pt)
PT (1) PT1618128E (pt)
RU (1) RU2342400C2 (pt)
SI (1) SI1618128T1 (pt)
UA (1) UA91180C2 (pt)
WO (1) WO2004094469A1 (pt)
ZA (1) ZA200508276B (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602004028000D1 (de) * 2003-04-23 2010-08-19 Max Planck Gesellschaft Tuberkulose vaccine mit verbesserter effizienz
EP1649869A1 (en) * 2004-10-21 2006-04-26 Vakzine Projekt Management GmbH Combination of a recombinant mycobacterium and a biologically active agent as a vaccine
ES2366622T3 (es) 2004-12-01 2011-10-24 Aeras Global Tb Vaccine Foundation Cepas de bcg recombinante con capacidad potenciada para escapar del endosoma.
EP2818178A1 (en) * 2008-01-11 2014-12-31 The Government of The United States of America as represented by The Secretary, Department of Health and Human Services Polypeptide vaccine and vaccination strategy against mycobacterium
WO2011031139A1 (en) 2009-09-09 2011-03-17 Universiteit Utrecht Holding B.V. An ataq protein or a part thereof as a vaccine
SA110310855B1 (ar) 2009-11-13 2014-09-16 Laboratories Leti S L Unipersonal استخدام مصدر l3 و/ أو l5 كلقاح أو كوسيلة تشخيصية لمرض طفيلي
BR112013004389A2 (pt) 2010-08-27 2016-05-17 Pantarhei Bioscience Bv método imunoterapêutico para tratamento do câncer de próstata
KR101907222B1 (ko) * 2010-09-20 2018-10-11 바크지네 프로제크트 마나게멘트 게엠베하 인간에게 사용하기 위한 백신으로서 재조합 마이코박테리움
PL2638062T3 (pl) 2010-11-10 2018-11-30 Laboratorios Leti, S.L. Nowy adiuwant
KR101832019B1 (ko) 2010-12-21 2018-02-23 막스-플랑크-게젤샤프트 츄어 푀르더룽 데어 비쎈샤프텐 에.파우. 백신으로서의 재조합 마이코박테리움
SG191331A1 (en) * 2010-12-21 2013-07-31 Max Planck Gesellschaft Determination of the efficacy of an anti-mycobacterial vaccination
RU2520078C1 (ru) * 2013-04-25 2014-06-20 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации (ФГБУ "НИИЭМ им. Н.Ф. Гамалеи" Минздрава России) СПОСОБ ПОЛУЧЕНИЯ ИММУНОГЕННОЙ КОМПОЗИЦИИ НА ОСНОВЕ ГИБРИДНОГО БЕЛКА Ag85A-DBD И ДЕКСТРАНА, РЕКОМБИНАНТНАЯ ПЛАЗМИДА pAg85A-DBD, ШТАММ Escherichia coli [pREP4, pAg85A-DBD], ХИМЕРНЫЙ БЕЛОК Ag85A-DBD
WO2016080830A2 (en) 2014-11-18 2016-05-26 Pantarhei Bioscience B.V. Immunotherapeutic method for treating pancreatic cancer
EP3090757A1 (en) * 2015-05-04 2016-11-09 Vakzine Projekt Management GmbH Recombinant mycobacterium as an immunotherapeutic agent for the treatment of cancer
US20180256633A1 (en) 2015-09-18 2018-09-13 Rijksuniversiteit Groningen Long chain inulin for stimulating an immune response
KR101825439B1 (ko) * 2016-04-15 2018-02-05 배재대학교 산학협력단 염산 처리에 의한 그람양성 박테리아 고스트의 제조 방법
US11717565B2 (en) * 2017-04-07 2023-08-08 Chengdu Anyong Dingye Biotechnology Co., Ltd. Recombinant BCG overexpressing phoP-phoR
WO2019021064A1 (en) * 2017-07-25 2019-01-31 Aurora Labs Ltd CONSTRUCTION OF SOFTWARE DELTA UPDATES FOR VEHICLE ECU SOFTWARE AND TOOL-BASED ANOMALY DETECTION
RU2678175C1 (ru) * 2018-03-16 2019-01-23 федеральное государственное бюджетное учреждение "Научно-исследовательский институт гриппа имени А.А. Смородинцева" Министерства здравоохранения Российской Федерации (ФГБУ "НИИ гриппа им. А.А. Смородинцева" Минздрава России) Рекомбинантный штамм вируса гриппа A/PR8/HK-NS80E85A, экспрессирующий фрагменты антигенов ESAT-6 и Ag85A M.tuberculosis, для получения векторной вакцины против туберкулеза
CN111979162B (zh) * 2019-05-22 2024-02-13 上海市公共卫生临床中心 重组卡介苗菌株、其制备方法和用途
WO2021228363A1 (en) 2020-05-11 2021-11-18 Vakzine Projekt Management Gmbh Prevention of infectious diseases by modulating the immune system
EP4149529A1 (en) 2020-05-11 2023-03-22 Vakzine Projekt Management GmbH Prevention of infectious diseases by modulating the immune system
JPWO2022075458A1 (pt) * 2020-10-09 2022-04-14
MX2024000980A (es) 2021-07-22 2024-06-21 Serum Life Science Europe Gmbh Mycobacterium recombinante como un agente inmunoterapeutico para la terapia de segunda linea contra carcinoma de vejiga urinaria.
EP4122491A1 (en) 2021-07-22 2023-01-25 Vakzine Projekt Management GmbH Recombinant microbacterium as an immunotherapeutic agent for the second-line therapy of bladder carcinoma

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100533818B1 (ko) * 1996-12-18 2005-12-07 스탠포드 룩 리미티드 면역계의 ｔｈ2 활성의 하향 조절을 위한 마이코박테리움 박케
EP0902086A1 (en) 1997-08-22 1999-03-17 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Tuberculosis vaccine
DE602004028000D1 (de) * 2003-04-23 2010-08-19 Max Planck Gesellschaft Tuberkulose vaccine mit verbesserter effizienz

Also Published As

Publication number Publication date
PT1618128E (pt) 2010-10-13
CN1798762B (zh) 2010-04-28
AU2004232485B2 (en) 2009-11-26
HK1091217A1 (zh) 2007-01-12
CY1110793T1 (el) 2015-06-10
RU2005136354A (ru) 2006-03-20
CU23608A3 (es) 2010-12-08
WO2004094469A1 (en) 2004-11-04
EP1618128B1 (en) 2010-07-07
BRPI0409789B8 (pt) 2021-05-25
ATE473238T1 (de) 2010-07-15
MXPA05011360A (es) 2005-11-28
US20120027794A1 (en) 2012-02-02
EP1618128A1 (en) 2006-01-25
UA91180C2 (ru) 2010-07-12
JP4662925B2 (ja) 2011-03-30
US8545854B2 (en) 2013-10-01
PL1618128T3 (pl) 2010-12-31
US7988980B2 (en) 2011-08-02
HRP20100395T1 (hr) 2010-09-30
KR20050114281A (ko) 2005-12-05
BRPI0409789B1 (pt) 2018-10-16
ZA200508276B (en) 2006-06-28
RU2342400C2 (ru) 2008-12-27
CA2523084C (en) 2012-09-04
JP2007524367A (ja) 2007-08-30
CN1798762A (zh) 2006-07-05
ES2344698T3 (es) 2010-09-03
CA2523084A1 (en) 2004-11-04
KR101101263B1 (ko) 2012-01-04
AU2004232485A1 (en) 2004-11-04
DE602004028000D1 (de) 2010-08-19
DK1618128T3 (da) 2010-10-18
SI1618128T1 (sl) 2010-11-30
US20070134267A1 (en) 2007-06-14

Similar Documents

Publication Publication Date Title
BRPI0409789A (pt) vacina de tuberculose com eficácia aperfeiçoada
DK1007686T3 (da) Tuberkulosevaccine
EA200700849A1 (ru) Первичная/бустерная противомалярийная вакцина
WO2007062656A3 (en) A nucleotide vaccine
KR100469936B1 (ko) 사스 바이러스 항원의 세포표면 발현벡터 및 상기 벡터에의해 형질전환된 미생물
ATE354662T1 (de) Modifizierte hpv e6- und e7-gene und -proteine als impfstoff
NZ598605A (en) Vaccine against african horse sickness virus
BRPI0416916A (pt) promotores para expressão em vìrus de vacìnia modificada ankara
WO2007024947A3 (en) Canine influenza vaccines
EA200702254A1 (ru) Вакцинная композиция, содержащая в-субъединицу термолабильного токсина e.coli и антиген и адъювант
DK1290160T3 (da) Humane Pellino-polypeptider
BR0313135A (pt) Epìtopos de células t em eritropoietina
NZ603854A (en) West nile virus vaccine
WO2007016598A3 (en) Influenza vaccine compositions and methods of use thereof
DE60239753D1 (de) Impfstoff gegen infektiöses lachsanämievirus
MX2010010025A (es) Proteina de fusion con direccionamiento de antigenos vacunales a celulas presentadoras de antigeno y sus aplicaciones.
TW200510460A (en) Antimicrobial polypeptides
DK1962889T3 (da) Immunogent polypeptid nestående af tumorantigenafledte optimerede kryptiske peptider samt anvendelser deraf
EP1005365A4 (en) ABUNDANT EXTRACELLULAR PRODUCTS AND METHODS OF PRODUCING AND USING THE SAME
WO2004067032A3 (en) Identification of gene sequences and proteins involved in vaccinia virus dominant t cell epitopes
TW200502253A (en) Antimicrobial polypeptides
BR0308180A (pt) protéinas de superfìcie de leptospira
GB0409559D0 (en) Polypeptide
ATE408692T1 (de) Kälteinduzierter expressionsvektor
DE602005018369D1 (de) Neue proteine, z.b. zur verwendung für die in-vitro-isolierung und prävention von legionella pneumophila-infektionen

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 16/10/2018, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 23/04/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF